Diagnosis and treatment of apical hypertrophic cardiomyopathy of the left ventricle

This article presents a case of diagnosis and treatment of a rare form of left ventricular (LV) hypertrophic cardiomyopathy (HCMP), asymmetric topical HCMP without obstruction of the LV outflow tract, and raises the issue of diagnosis and treatment of rare forms of this disease. In the Federal Center for Cardiovascular Surgery in 2019–2020, 5 cases of asymmetric hypertrophic apical cardiomyopathy were observed and documented with echocardiography (EchoCG), cardiac magnetic resonance imaging (MRI), and Holter ECG monitoring. A 60-year-old female patient underwent a comprehensive evaluation, including physical examination, EchoCG, MRI, Holter ECG monitoring, and coronary angiography. Apical HCMP was detected. The clinical picture was explainable from the perspective of functional and structural alterations in the LV myocardium, where full obstruction of the cardiac apex develops during systole. The small LV cavity is unable to provide effective hemodynamics. Changed small coronary arteries also contribute to this disorder, which, in results, affects myocardial oxygen supply. The administered therapy included antiplatelets, beta-blockers, angiotensin II receptor blockers, diuretics, and ranolazine. The effect of therapy was assessed as positive. Risk of sudden death, according to European Guidelines, 2014 was 0.86 %.

1. Trisvetova E.L. Hypertrophic cardiomyopathy: etiology, clinic, diagnosis, treatment. Medical news. 2007;9:19–24.

2. Nelipa E.A., Salamatina L.V., Urvantseva I.A., Karnysheva S.I., Raĭkovskaia L.R. A case of diagnosis of asymmetric apical hypertrophic cardiomyopathy of the left ventricle with intraventricular obstruction. Therapeutic Archive. 2014;86(4):72–4.

3. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. The American Journal of Cardiology. 1994;73(8):577–80. DOI: 10.1016/0002-9149(94)90337-9

4. Shaposhnik I.I., Bogdanov D.V. Differential diagnosis of hypertrophic cardiomyopathy and hypertrophy of the myocardium secondary origin. Russian Medical Journal. 2014;22(12):923–7.

5. Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y, Hayashi T et al. Giant T Wave Inversion as a Manifestation of Asymmetrical Apical Hypertrophy (AAH) of the Left Ventricle: Echocardiographic and Ultrasono-cardiotomographic Study. Japanese Heart Journal. 1976;17(5):611–29. DOI: 10.1536/ihj.17.611

6. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761–96. DOI: 10.1161/CIR.0b013e318223e230

7. Bugała K, Płazak W, Konieczyńska M, Podolec P. Apical hypertrophic cardiomyopathy in an adult (RCD code: III-2A). Journal of Rare Cardiovascular Diseases. 2016;2(6):185–8. DOI: 10.20418/jrcd.vol2no6.225

8. Krylova N.S., Kovalevskaya E.A., Poteshkina N.G., Demkina A.E., Khashieva F.M. Sudden death in hapertrophic cardiomyopathy: the search for new risk factors. Russian Journal of Cardiology. 2017;2:62–7. DOI: 10.15829/1560-4071-2017-2-62-67

9. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. The American Journal of Cardiology. 1981;47(3):532–8. DOI: 10.1016/0002-9149(81)90535-X

10. Diaconu CC, Dumitru N, Fruntelata AG, Lacau S, Bartos D. Apical Hypertrophic Cardiomyopathy: The Ace-of-Spades as the Disease Card. Acta Cardiologica Sinica. 2015;31(1):83–6. DOI: 10.6515/acs20140310c

11. Klarich KW, Attenhofer Jost CH, Binder J, Connolly HM, Scott CG, Freeman WK et al. Risk of Death in Long-Term Follow-Up of Patients With Apical Hypertrophic Cardiomyopathy. The American Journal of Cardiology. 2013;111(12):1784–91. DOI: 10.1016/j.amjcard.2013.02.040

12. Semsarian C, Ingles J, Maron MS, Maron BJ. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2015;65(12):1249–54. DOI: 10.1016/j.jacc.2015.01.019

13. Amosova E.N. Cardiomyopathy. -Kiev: Book Plus;1999. – 216 p.

14. Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. The American Journal of Cardiology. 2003;92(10):1183–6. DOI: 10.1016/j.amjcard.2003.07.027

15. Sakamoto T, Amano K, Hada Y, Tei C, Takenaka K, Hasegawa I et al. Asymmetric apical hypertrophy: ten years experience. Postgraduate Medical Journal. 1986;62(728):567–70. DOI: 10.1136/pgmj.62.728.567

16. Yamaguchi H, Ishimura T, Nishiyama S, Nagasaki F, Nakanishi S, Takatsu F et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): Ventriculographic and echocardiographic features in 30 patients. The American Journal of Cardiology. 1979;44(3):401–12. DOI: 10.1016/0002-9149(79)90388-6

17. Nesukai Ye.G., Adarichev V.V., Titov Ye.Yu., Giresh I.I. Apical hypertrophic cardiomyopathy. A case report and a literature review. Arterial Hypertension. 2017;1(51):60–71. DOI: 10.22141/2224-1485.1.51.2017.96251

18. Tseluiko V.I., Kinoshenko K.Yu., Mishchuk N.E. Evaluation of left ventricular myocardial deformity in clinical practice. Lіki Ukraini. 2014;9(185):52–6.

19. Gentry JL, Mentz RJ, Hurdle M, Wang A. Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). Journal of the American College of Cardiology. 2016;68(16):1815–7. DOI: 10.1016/j.jacc.2016.07.758